10 Year Financial Data of Alexion Pharmaceuticals, Inc. (ALXN)

102.67 (1y: +11%)

Market Cap	19.52 B	P/E(ttm)	70.70
Enterprise Value	18.65 B	P/B	10.30

ALXN- NAS (USA)
Alexion Pharmaceuticals, Inc.

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$102.67

2 Good Signs

Bookmark

Annual Rates (per share)	10 yrs*	5 yrs*	12 months*
Revenue Growth (%)	124.5	40.5	37.4
EBITDA Growth (%)	0	70.6	62.1
Free Cash Flow Growth (%)	0	168.8	11.6
Book Value Growth (%)	26.4	55.3	68.3

*12-month growth rate is calculated with the per share revenue (EBITDA, FCF, earnings) of the last 12 months over the per share revenue (EBITDA, FCF, earnings) over the previous 12 months. 5-year and 10-year growth rates are calculated with least-square regression based on the 5-year and 10-year numbers.

Trendline:

Export:

Print This Table Print

See this page for the explanation of the data and charts * All numbers are in millions except for per share data

Per Share Data	Annuals											Quarterly
Fiscal Period	Jul03	Jul04	Jul05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue per Share ($)	0.01	0.05	0.01	0.01	0.50	1.44	2.14	2.91	4.08	5.71	6.14	1.26	1.39	1.46	1.59	1.70
EBITDA per Share	-1.09	-0.77	-0.96	-1.05	-0.65	0.23	0.55	0.89	1.30	2.16	2.38	0.39	0.45	0.74	0.57	0.62
Free Cashflow per Share	-1.27	-0.87	-0.90	-1.12	-1.44	0.03	0.28	0.80	1.29	1.96	1.85	0.30	0.49	0.67	0.48	0.21
Earnings per Share ($)	-1.16	-0.86	-0.98	-1.04	-0.64	0.20	1.63	0.52	0.91	1.28	1.45	0.23	0.18	0.46	0.40	0.41
Book Value per Share	1.65	1.99	0.61	0.98	0.70	1.37	3.80	4.62	5.91	9.93	10.50	6.24	8.88	9.31	9.80	10.50
Month End Stock Price	4.20	3.98	6.51	10.10	18.76	18.10	24.41	40.28	71.50	93.74	92.14	92.86	99.30	114	93.74	92.14
Ratios	Annuals											Quarterly
Fiscal Period	Jul03	Jul04	Jul05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Return on Equity %	-70.20	-42.90	-161	-106	-90.90	13.40	42.90	11.30	15.50	12.90	15.60	14.80	8.40	19.60	16.40	15.60
Return on Assets %	-31.70	-23.20	-43.80	-39.40	-27.60	6.90	37.50	9.60	12.60	9.70	12.40	9.20	6.00	14.80	12.40	12.40
Return on Capital - Joel Greenblatt %	-5,487	-1,294	--	-776	-59.90	17.50	31.40	48.70	68.40	112	105	75.20	109	160	120	105
Debt to Equity	1.03	0.72	2.22	1.41	1.92	0.58	0.02	0.01	0.00	0.08	0.07	0.29	0.13	0.09	0.08	0.07

Gross Margin %	100.00	100.00	100.00	100.00	90.70	89.10	88.40	88.10	88.10	88.90	89.60	88.40	88.50	88.70	89.70	89.60
Operating Margin %	-9,504	-1,529	-10,370	-8,799	-139	13.40	22.50	27.80	29.50	35.70	34.50	28.60	30.50	48.50	33.70	34.50
Net Margin %	-9,631	-1,608	-10,221	-8,441	-128	12.80	76.30	17.90	22.40	22.50	24.30	18.60	13.20	31.30	25.30	24.30

Days Sales Outstanding	421	435	451	385	252	105	107	114	114	95.10	87.00	99.40	93.70	96.30	83.90	87.00
Days Inventory	--	--	--	--	1,794	641	331	352	319	273	263	299	271	247	260	263
Inventory Turnover	--	--	--	--	0.20	0.60	1.10	1.00	1.10	1.30	0.30	0.30	0.30	0.40	0.40	0.30

Debt to Revenue	141	26.89	141	113	2.70	0.56	0.03	0.01	0.00	0.13	0.44	1.45	0.83	0.55	0.47	0.44
COGS to Revenue	--	--	--	--	0.09	0.11	0.12	0.12	0.12	0.11	0.10	0.12	0.12	0.11	0.10	0.10
Inventory to Revenue	--	--	--	1.49	0.46	0.19	0.11	0.12	0.10	0.08	0.30	0.38	0.34	0.31	0.30	0.30
Interest Exp. to Revenue %	-215	-94.08	-576	336	-3.46	-0.93	-0.16	-0.13	-0.10	-0.49	-0.22	-0.93	-0.76	-0.52	-0.07	-0.22

Asset Turnover	0.00	0.01	0.00	0.01	0.22	0.54	0.49	0.54	0.56	0.43	0.13	0.12	0.11	0.12	0.12	0.13
Buyback Ratio	0.20	172	3.40	117	50.90	-87.20	-10.40	-38.70	-20.40	-181	--	-34.80	-1,231	0.10	--	--
Income Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Jul03	Jul04	Jul05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue	0.88	4.61	1.06	1.56	72.04	259	387	541	783	1,134	1,228	245	275	294	321	339
Cost of Goods Sold	--	--	--	--	6.70	28.37	45.06	64.44	93.14	126	133	28.27	31.61	33.19	33.15	35.27
Gross Profit	0.88	4.61	1.06	1.56	65.35	231	342	477	690	1,008	1,095	216	243	261	287	304

Selling, General, &Admin. Expense	10.62	14.46	18.95	54.88	96.14	134	173	227	308	385	406	87.24	94.86	89.96	113	109
Research &Development	71.04	59.84	91.39	83.23	68.96	62.58	81.92	98.39	137	223	252	45.41	59.64	54.28	63.41	74.54
Earnings Before DDA	-79.62	-66.86	-107	-133	-94.83	42.22	99.53	166	248	428	476	75.91	89.25	149	114	123

Depreciation, Depletion and Amortization	3.73	3.59	3.68	3.71	4.93	7.61	12.47	15.79	17.62	23.89	24.28	5.88	5.54	6.19	6.27	6.27

Operating Income	-83.35	-70.45	-110	-137	-99.76	34.61	87.06	151	231	404	451	70.04	83.71	143	108	117
Interest Income/Expense	-1.89	-4.34	-6.13	5.24	-2.49	-2.41	-0.61	-0.70	-0.79	-5.56	-4.57	-2.29	-2.08	-1.54	-0.22	-0.73
Net Income	-84.47	-74.10	-109	-132	-92.29	33.15	295	97.03	175	255	292	45.41	36.26	92.18	80.97	82.22

Earnings per Share ($)	-1.16	-0.86	-0.98	-1.04	-0.64	0.20	1.63	0.52	0.91	1.28	1.45	0.23	0.18	0.46	0.40	0.41
Total Shares Outstanding	72.84	86.49	111	127	145	180	181	186	192	199	199	195	197	201	201	199
Balance Sheet	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Jul03	Jul04	Jul05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Cash and cash equivalents	215	267	195	217	106	138	176	362	541	990	1,023	359	806	906	990	1,023
Accounts Receivable	1.01	5.49	1.32	1.64	49.65	74.48	114	169	244	296	324	267	283	311	296	324
Inventory	--	--	--	2.31	32.91	49.82	40.89	62.17	81.39	94.52	102	92.91	94.11	90.05	94.52	102
Other Current Assets	3.34	4.34	4.44	2.33	17.05	14.79	42.62	54.05	74.73	116	101	92.24	93.12	103	116	101
Total Current Assets	220	276	201	223	205	277	373	647	941	1,496	1,550	812	1,276	1,410	1,496	1,550

Property, Plant and Equipment	12.28	11.37	11.55	39.14	104	140	165	162	166	166	165	166	165	165	166	165
Intangible Assets	19.95	19.95	19.95	19.95	19.95	52.28	48.54	44.10	171	900	899	941	931	902	900	899
Other Long Term Assets	14.09	11.92	15.46	51.61	4.77	8.29	200	159	116	52.01	71.84	98.45	85.68	28.03	52.01	71.84
Total Assets	266	320	248	334	334	478	786	1,012	1,395	2,614	2,686	2,017	2,458	2,506	2,614	2,686

Accounts Payable	14.52	14.98	23.82	27.17	37.40	79.86	83.19	123	178	228	213	223	294	270	228	213
Current Portion of Long-Term Debt	--	3.92	0.08	0.07	0.27	2.80	0.42	0.72	1.45	48.00	48.00	108	48.00	48.00	48.00	48.00
Other Current Liabilities	0.59	0.78	0.82	0.59	0.04	1.77	1.65	14.74	51.24	84.43	35.20	22.79	32.84	44.10	84.43	35.20
Total Current Liabilities	15.11	19.67	24.71	27.82	37.71	84.42	85.26	139	230	360	296	354	375	362	360	296

Long-Term Debt	124	120	150	176	194	141	10.42	4.46	0.18	101	101	247	180	113	101	101
Other Long-Term Liabilities	6.76	7.38	5.59	4.76	0.59	4.71	2.36	9.32	29.85	182	199	204	153	158	182	199
Total Liabilities	146	147	180	209	233	231	98.05	152	260	643	596	804	708	633	643	596

Common Stock	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Retained Earnings	-265	-339	-448	-638	-729	-696	-401	-304	-129	126	208	-83.21	-46.95	45.23	126	208
Additional Paid-In Capital	385	513	519	764	834	941	1,094	1,173	1,262	1,852	1,900	1,292	1,783	1,828	1,852	1,900
Treasury Stock	-0.60	-0.60	-0.60	-1.26	-1.26	-1.26	-2.68	-2.68	-2.68	-14.23	-49.34	-2.68	-2.68	-2.68	-14.23	-49.34
Total Equity	120	173	67.67	125	102	247	688	860	1,134	1,971	2,090	1,213	1,750	1,872	1,971	2,090
Cashflow Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Jul03	Jul04	Jul05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Net Income	-84.47	-74.10	-109	-132	-92.29	33.15	295	97.03	175	255	292	45.41	36.26	92.18	80.97	82.22
Depreciation, Depletion and Amortization	3.73	3.59	3.68	3.71	4.93	7.61	12.47	15.79	17.62	23.89	24.28	5.88	5.54	6.19	6.27	6.27
Cash Flow from Others	-8.46	-1.49	8.19	17.89	-52.25	12.44	-194	48.08	77.15	132	78.40	11.52	59.73	42.95	17.71	-41.99
Cash Flow from Operations	-89.20	-71.99	-96.88	-110	-140	53.20	114	161	270	411	394	62.81	102	141	105	46.50

Investment for Property, Plant & Equipement	-3.07	-3.14	-2.98	-31.86	-68.83	-48.36	-63.02	-12.84	-21.98	-21.85	-23.57	-3.77	-4.25	-6.24	-7.59	-5.49
Cash Flow from Acquisitions	--	--	--	--	--	--	--	--	-106	-606	-0.31	-605	-0.31	--	--	--
Cash Flow from Investing	66.31	33.15	1.63	53.91	3.08	-38.65	-81.42	-89.32	-33.72	-628	-23.96	-609	-4.56	-6.24	-7.59	-5.57

Net Issuance of Stock	0.16	127	3.74	154	47.01	28.89	30.73	37.55	35.77	451	400	15.82	446	-0.05	-11.55	-35.11
Net Issuance of Debt	--	--	30.00	25.78	17.84	-0.59	-44.35	-0.65	-0.73	149	-206	355	-127	-67.35	-11.36	--
Other Financing	--	--	-4.76	--	-0.00	--	-0.65	1.97	4.02	66.72	104	-6.11	31.70	30.72	10.41	30.80
Cash Flow from Financing	0.16	127	28.99	179	64.84	28.31	-14.27	38.87	39.05	666	297	365	351	-36.69	-12.51	-4.31

Net Change in Cash	-22.73	88.38	-66.27	123	-71.51	42.69	19.16	110	274	449	664	-181	447	99.32	83.98	33.46

Free Cash Flow	-92.27	-75.13	-99.86	-142	-208	4.84	50.83	148	248	389	371	59.04	97.28	135	97.37	41.00
Valuation Ratios (Daily)	Annuals											Quarterly
Fiscal Period	Jul03	Jul04	Jul05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

PE Ratio(ttm)
Price to Tangible Book
Price-to-Free-Cash-Flow ratio
PS Ratio
EV-to-Revenue
EV-to-EBITDA
EV-to-EBIT
Earnings Yield (Joel Greenblatt)
Forward Rate of Return
Shiller PE Ratio
Valuation and Quality	Annuals											Quarterly
Fiscal Period	Jul03	Jul04	Jul05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Market Cap
Enterprise Value
Month End Stock Price
Net Cash (per share)
Net Current Asset Value (per share)
DCF (per share)
Median PS (per share)
Peter Lynch Fair Value (per share)
Graham Number (per share)
Altman Z-Score
Piotroski F-Score
Beneish M-Score

Switch to Another Stock:

ALXN Quarterly/Annuals Reports

ALXN: 10-Q - ALEXION PHARMACEUTICALS INC (0000899866) (Filer): (10-Q) - 2012-10-29
ALXN: 10-Q - ALEXION PHARMACEUTICALS INC (0000899866) (Filer): (10-Q) - 2012-07-27
ALXN: 10-Q - ALEXION PHARMACEUTICALS INC (0000899866) (Filer): (10-Q) - 2012-05-02
ALXN: 10-K - ALEXION PHARMACEUTICALS INC (0000899866) (Filer): (10-K) - 2012-02-17
ALXN: 10-Q - ALEXION PHARMACEUTICALS INC (0000899866) (Filer): (10-Q) - 2011-10-31

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles

ALXN Quarterly/Annuals Reports